{"contentid": 488517, "importid": NaN, "name": "MAA filed for Legend Biotech and Janssen\u00e2\u0080\u0099s for cilta-cell in Europe", "introduction": "Legend Biotech, a clinical stage CAR-T immuno-oncology biotech being spun out of Hong Kong-listed GenScript Biotech, revealed on Friday that a Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMA) seeking approval of ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma.", "content": "<p>Legend Biotech (Nasdaq: LEGN), a clinical stage CAR-T immuno-oncology biotech being spun out of Hong Kong-listed GenScript Biotech, revealed on Friday that a Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMA) seeking approval of ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma.</p>\n<p>The request was ma<a id=\"publish\" class=\"publish\" title=\"Publish\"></a>Publishde by Legend&rsquo;s collaborator, Janssen Biotech, a part of US healthcare giant Johnson &amp; Johnson (NYSE: JNJ). In December 2017, Legend Biotech entered into an exclusive worldwide license and collaboration <a href=\"https://www.thepharmaletter.com/article/janssen-moves-into-car-t-space-via-chinese-deal\">agreement with Janssen Biotech</a>, to develop and commercialize cilta-cel, which involved an upfront payment of $350 million.</p>\n<p>Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated as a treatment for multiple myeloma. The MAA is based on positive results from a Phase Ib/II CARTITUDE-1 study.</p>\n<p>&ldquo;Today&rsquo;s submission is a testimony to the promising results we have seen from the CARTITUDE-1 study showing the efficacy and safety of cilta-cel for treating patients with multiple myeloma who are heavily pre-treated and in need of treatment options,&rdquo; said Ying Huang, chief executive and chief financial officer and of Legend Biotech. &ldquo;We are proud of our collaboration with Janssen and look forward to bringing this personalized treatment to patients in the EU following the accelerated assessment.&rdquo;</p>\n<p>The <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.legendbiotech.com%2Fpdf%2FLEGN_PR_02012020.pdf&amp;esheet=52421364&amp;newsitemid=20210430005260&amp;lan=en-US&amp;anchor=EMA%26%238217%3Bs+Committee+for+Medicinal+Products+for+Human+Use+%28CHMP%29+granted+accelerated+assessment&amp;index=2&amp;md5=dd8ff4d7d73526b44cb5a6e2a843b757\">EMA&rsquo;s Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment&nbsp;</a> for this MAA. An accelerated assessment is granted when the CHMP determines that a medicinal product is of major public health interest and therapeutic innovation and can significantly reduce the review timelines to evaluate an MAA. Cilta-cel previously received a PRIority MEdicines (PRIME) designation from the EMA. A Biologics License Application (BLA) seeking approval of cilta-cel based on the CARTITUDE-1 study is currently under review with the US Food and Drug Administration.</p>", "date": "2021-05-01 15:25:00", "meta_title": "MMA filed for Legend Biotech and Janssen\u00e2\u0080\u0099s for cilta-cell in Europe", "meta_keywords": "Janssen, Johnson & Johnson, Legend Biotech, Cltacabtagene autoleucel, Cilta-cel, MAA, Multiple myeloma, EMA", "meta_description": "MMA filed for Legend Biotech and Janssen\u00e2\u0080\u0099s for cilta-cell in Europe", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-01 15:24:19", "updated": "2021-05-01 23:51:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/mma-filed-for-legend-biotech-and-janssen-s-for-cilta-cell-in-europe", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "legend_biotech_large.jpg", "image2id": "legend_biotech_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Immuno-oncology", "topic_tag": "European Medicines Agency, Focus On, One to Watch Companies, Regulation", "geography_tag": "Europe, USA", "company_tag": "Janssen, Johnson & Johnson, Legend Biotech", "drug_tag": "ciltacabtagene autoleucel", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-01 15:25:00"}